Cancer is caused by cellular defects that produce genetic changes that cause uncontrolled cell proliferation and the loss of the characteristics that define the cell type of origin. As many combinations of genetic changes can cause cancer in the same cell type, cancers that are classified as a cancer type, such as Non-Small Cell Lung Cancer (NSCLC), are really different forms of disease that respond differently to chemotherapy. The hypothesis that this project will test is that the set of mutations that drive a particular typ of cancer (an oncogenotype), will also create weaknesses in that cancer cell type that are not shared with normal cells or cancers with a different oncogenotype. This project will extend the work of a pilot phase CTDD project that has designed methods to identify vulnerabilities in cancers that are caused by their underlying mutational status. Our methods rely upon the use of novel chemical probes and thus are biased towards detecting potentially """"""""druggable"""""""" targets likely to be of therapeutic use. We will screen a large panel of NSCLC and SCLC cell lines with a unique natural products library created at UT Southwestern. In the pilot phase of the CTDD we have screened a subset of this library with genome wide siRNA libraries and 200,000 chemical compounds, allowing us to categorize the lung cancer panel according to vulnerabilities to these reagents. In this current project we will identify natural products that ae toxic to groups of cell lines that are related by the mutations they contain and their sensitivitie to chemotherapeutic agents and siRNA probes. We will identify the mode of action and molecular targets of natural product chemical probes of interest. To do this, we will employ a new bioinformatics tool (FUSION) we have developed to rapidly link the activity of an unknown chemical probe to the activity of siRNAs, miRNAs and compounds with known mode of action. By sequencing the exome of each cell line and comparing mutations found in cell lines to the mutations found in tumors by The Cancer Genome Atlas, we will determine which mutations are linked to each vulnerability, so that this information can be used clinically to identify tumors tht might be treated by targeting the vulnerability. We will validate each vulnerability by determining if the growth of tumor xenografts in mice is antagonized by a chemical probe that targets the vulnerability and/or by delivering siRNAs against the target to xenografts in mice, using nanoparticle delivery. Because we know the response of the cell lines in our panel to known chemotherapeutic drugs, we will be able to report any linkage of an oncogenotype to clinically approved drugs as soon as the functional oncogenotype is defined. Although this project will begin by developing methods to categorize NSCLC and SCLC, these methods can be applied to any cancer for which there is a sufficiently large collection of tumor-derived cell lines. We wil work with the CTDD to apply our tools and natural products library to other types of cancer. At UT SW we have access to a growing panel of ovarian cancers that provide an opportunity for future study.
This project will extend the work of a pilot phase CTDD project that has designed methods to identify vulnerabilities in cancers that are caused by their underlying mutational status. Our methods rely upon the use of novel chemical probes and thus are biased towards detecting potentially druggable targets likely to be of therapeutic use and, in the course of this work, we will identify for the first time the different molecular diseases tht cause small cell and non-small cell lung cancer. We will identify mutations that can be used to identify these diseases, as well as potential new drug targets and the sensitivity to existing chemotherapeutic agents for each disease.!
|Kim, Jiyeon; Hu, Zeping; Cai, Ling et al. (2017) CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells. Nature 546:168-172|
|Tagal, Vural; Wei, Shuguang; Zhang, Wei et al. (2017) SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun 8:14098|
|Zhou, Xiaorong; Updegraff, Barrett L; Guo, Yabin et al. (2017) PROTOCADHERIN 7 Acts through SET and PP2A to Potentiate MAPK Signaling by EGFR and KRAS during Lung Tumorigenesis. Cancer Res 77:187-197|
|Eskiocak, Banu; McMillan, Elizabeth A; Mendiratta, Saurabh et al. (2017) Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. Cancer Discov 7:832-851|
|Vaden, Rachel M; Oswald, Nathaniel W; Potts, Malia B et al. (2017) FUSION-Guided Hypothesis Development Leads to the Identification of N?,N?-Dimethyladenosine, a Marine-Derived AKT Pathway Inhibitor. Mar Drugs 15:|
|Li, Zenggang; Ivanov, Andrei A; Su, Rina et al. (2017) The OncoPPi network of cancer-focused protein-protein interactions to inform biological insights and therapeutic strategies. Nat Commun 8:14356|
|Gao, Boning; Huang, Chunxian; Kernstine, Kemp et al. (2017) Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions. Oncotarget 8:11114-11126|
|Pagano, Paul C; Tran, Linh M; Bendris, Nawal et al. (2017) Identification of a Human Airway Epithelial Cell Subpopulation with Altered Biophysical, Molecular, and Metastatic Properties. Cancer Prev Res (Phila) 10:514-524|
|Deb, Dhruba; Rajaram, Satwik; Larsen, Jill E et al. (2017) Combination Therapy Targeting BCL6 and Phospho-STAT3 Defeats Intratumor Heterogeneity in a Subset of Non-Small Cell Lung Cancers. Cancer Res 77:3070-3081|
|Cooper, Jonathan M; Ou, Yi-Hung; McMillan, Elizabeth A et al. (2017) TBK1 Provides Context-Selective Support of the Activated AKT/mTOR Pathway in Lung Cancer. Cancer Res 77:5077-5094|
Showing the most recent 10 out of 33 publications